Human cytochromes mediating N-demethylation of fluoxetine in vitro

Psychopharmacology

Volumn 132, Issue 4, 1997, Pages 402-407

  Von Moltke, Lisa L ^a,b   Greenblatt, David J ^a,b   Duan, Su Xiang ^a,b   Schmider, Jürgen ^a,b   Wright, C Eugene ^a   Harmatz, Jerold S ^a,b   Shader, Richard I ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clinical Pharmacokinetics Unit   (United States)

Author keywords

Cytochromes; Fluoxetine; Human; Microsomes; N Demethylation

Indexed keywords

CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; FLUOXETINE; FLUVOXAMINE; FURAFYLLINE; KETOCONAZOLE; NORFLUOXETINE; QUINIDINE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; LYMPHOBLASTOID CELL; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FLUOXETINE; HUMANS; MICROSOMES, LIVER; SEROTONIN UPTAKE INHIBITORS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0030867820     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050362     Document Type: Article

References (42)

1. Altamura AC, Moro AR, Percudani M (1994) Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 26:201-214
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ (1995) Ketoconazole and sulfaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270
3. Bergstrom RF, Wolen RL, Lemberger L, Tenbarge JL, Masco HL (1986) Fluoxetine steady-state pharmacokinetics in depressed patients. Presented at the 133rd Annual Meeting of the American Pharmaceutical Association. San Francisco, Calif., March, 1986
4. Bourrié M, Meunier V, Berger Y, Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332
5. Brøsen K, Skjelbo E, Rasmussen BB, Poulson HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214
6. Ciraulo DA, Shader RI (1990) Fluoxetine drug-drug interactions. J Clin Psychopharmacol 10:48-50, 213-217
7. De Vane CL (1992) Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 53[2 Suppl]:13-20
8. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA expressed human cytochrome P450. Drug Metab Dispos 24:940-947
9. Gram LF (1994) Fluoxetine. New Engl J Med 331:1354-1361
10. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI (1996) Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 36:792-798
11. Hamelin BA, Turgeon J, Vallée F, Bélanger P-M, Paquet F, LeBel M (1996) The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 60:512-521
12. Harvey AT, Preskorn SH (1996) Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 16:273-285, 345-355
13. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K (1996a) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73-78
14. Jeppesen U, Loft S, Poulsen HE, Brøsen K (1996b) A fluvoxamine-caffeine interaction study. Pharmacogenetics 6:213-222
15. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM (1995) The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15:387-398
16. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96
17. Newton DJ, Wang RW, Lu AYH (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158
18. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681-693
19. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM (1993) Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53:401-409
20. Peyton AL, Carpenter R, Rutkowski K (1991) The stereospecific determination of fluoxetine and norfluoxetine enantiometers in human plasma by high-pressure liquid chromatography (HPLC) with fluorescence detection. Pharm Res 8:1528-1532
21. Schadel M, Wu D, Otton SV, Kalow W, Sellers EM (1995) Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 15:263-269
22. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1995) N-Demethylation of amitriptyline in vitro: role of cytochrome p-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 275:592-597
23. Schmider J, Greenblatt DJ, Harmatz JS, Shader RI (1996) Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. Br J Clin Pharmacol 41:593-604
24. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI (1997) Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin para-hydroxylation.Br J Clin Pharmacol (in press)
25. Segel IH (1975) Enzyme kinetics. Wiley, New York
26. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423
27. Sommi RW, Crismon ML, Bowden CL (1987) Fluoxetine: a serotonin specific, second-generation antidepressant. Pharmacotherapy 7:1-15
28. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J (1993) Selective serotonin reuptake inhibitors: metaanalysis of efficacy and acceptability. BMJ 306:683-687
29. Stevens JC, Wrighton SA (1993) Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 266:964-971
30. van Harten J (1993) Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 24:203-220
31. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI (1994a) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283
32. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI (1994b) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31
33. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI (1995a) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131
34. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI (1995b) Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 29 [Suppl 1]:33-44
35. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI (1996a) Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 16:104-112
36. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI (1996b) Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 128:398-407
37. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI (1996c) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379
38. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI (1996d) Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783-791
39. von Moltke LL, Duan SX, Greenblatt DJ, Fogelman SM, Schmider J, Harmatz JS, Shader RI (1997) Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biol Psychiatry 41:377-380
40. Wong DT, Bymaster FP, Engleman EA (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57:411-441
41. Xu Z-H, Xie H-G, Zhou H-H (1996) In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 42:518-521
42. Zhang YZ, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA (1992) Dextromethorphan: enhancing its systemic availability by way of low dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 51:647-655